In re application of Gregory M. Fahy

Application No.: 10/066,285

Page 2 of 9

Amendment to the Claims/Listing of Claims

Please amend claims 1-6, 36, 37, 39, 40, 43-49, 51, 59, 61 and 66, and cancel claims 67 and 68 as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Currently amended) A preservation solution for the liquid state hypothermic preservation of cells, tissues, and organs, said solution comprising a combination of polyglycerol and lactose in an amount effective to preserve the cells, tissues, and organs under hypothermic conditions having a total osmotic concentration in the range of 20 milliosmolal to 250 milliosmolal.
- 2. (Currently amended) The preservation solution of claim 1 wherein the lactose comprises alpha-lactose.
- 3. (Currently amended) The preservation solution of claim 1 wherein the polyglycerol [[is]] comprises from [[n =]] 2 to [[n =]] 200 monomer units.
- 4. (Currently amended) The preservation solution of claim 1 wherein the polyglycerol is decaglycerol or hexaglycerol.
- 5. (Currently amended) The preservation solution of claim 1 wherein the lactose is at a concentration from falls in the range of 11 mM to 250 mM.
- 6. (Currently amended) The preservation solution of claim 1 wherein the polyglycerol is at a concentration falls in the range of 10 mOsm to 250 mOsm.

In re application of Gregory M. Fahy

Application No.: 10/066,285

Page 3 of 9

7-35. (Cancelled)

- 36. (Currently amended) The preservation solution of claim 1 further comprising glutathione.
- 37. (Currently amended) The solution of claim [[36]] 1, further comprising chondroitin sulfate.
- 38. (Previously presented) The solution of claim 37 wherein the chondroitin sulfate is chondroitin sulfate A.
- 39. (Currently amended) The solution of claim 37, wherein the concentration of chondroitin sulfate is on the order falls in the range of 0.01% w/v to 1% w/v.
- 40. (Currently amended) The solution of claim [[37]] 1, further comprising chlorpromazine.
- 41. (Previously presented) The solution of claim 40, wherein the concentration of chlorpromazine is about 1-50 micrograms/ml.
- 42. (Previously presented) The solution of claim 41, wherein the concentration of chlorpromazine is about 2-10 micrograms/ml.
 - 43. (Currently amended) The solution of claim [[40]] 1, further comprising citrate.
 - 44. (Currently amended) The solution of claim [[43]] 1, further comprising calcium.

In re application of Gregory M. Fahy

Application No.: 10/066,285

Page 4 of 9

Atty. Dkt. No. 074066-0115

- 45. (Currently amended) The solution of claim [[44]] 1, further comprising magnesium.
 - 46. (Currently amended) The solution of claim [[45]] 1, further comprising adenine.
 - 47. (Currently amended) The solution of claim [[46]] 1, further comprising glucose.
 - 48. (Currently amended) The solution of claim [[47]] 1, further comprising acetate.
- 49. (Currently amended) The solution of claim [[48]] 1, further comprising phosphate buffer.
- 50. (Previously presented) The solution of claim 1, wherein the solution has an osmolality of less than about 350 mOsm.
- 51. (Currently amended) The solution of claim 1, <u>further comprising citrate and glucose</u>, wherein the sum of all impermeant species contributes the osmotic contributions of polyglycerol, lactose, citrate and glucose to the solution is 20-250 mOsm (milliosmolal) to the osmolality of the solution.
- 52. (Previously presented) A method for the preservation of cells, tissues, or organs under conditions of impaired cell volume homeostasis, comprising: contacting the cells, tissues, or organs with a solution of claim 1.
- 53. (Previously presented) A method for the preservation of cells, tissues, or organs under conditions of impaired cell volume homeostasis, comprising:

In re application of Gregory M. Fahy

Application No.: 10/066,285

Page 5 of 9

contacting the cells, tissues, or organs with a solution comprising polyglycerol in an amount effective to preclude or to reverse cell swelling.

- (Previously presented) The method of claim 53 wherein the contacting is via 54. intravenous or intra-arterial administration.
- (Previously presented) The method of claim 53 wherein the contacting is in vivo 55. via arterial organ perfusion or retrograde venous perfusion of an organ or vascularized tissue.
- (Previously presented) The method of claim 53 wherein the contacting is in vitro 56. via arterial organ perfusion or retrograde venous perfusion of an organ or vascularized tissue.
 - (Previously presented) The method of claim 53 wherein the contacting is via the 57. immersion of or bathing of affected cells, tissues, or organs.
 - 58. (Cancelled)
 - (Currently amended) The method of claim 53 wherein the polyglycerol [[is]] 59. comprises from [[n=]]2 to 200 monomer units in length.
 - (Previously presented) The method of claim 53 wherein the polyglycerol is 60. tetraglycerol, hexaglycerol, or decaglycerol.
 - (Currently amended) The method of claim 53 wherein the concentration of 61. polyglycerol in contact with the cell, tissue, or organ is at a concentration of from about 20 mOsm to 1,500 mOsm when in-contact with the cell, tissue, or organ.

In re application of Gregory M. Fahy

Application No.: 10/066,285

Page 6 of 9

- 62. (Previously presented) The method of claim 53 wherein the effective amount is an isotonic solution.
- 63. (Previously presented) The method of claim 53 wherein the effective amount is a hypertonic solution.
- 64. (Previously presented) A method for the preservation of cells, tissues, or organs under conditions of impaired cell volume homeostasis, comprising:

contacting the cells, tissues, or organs with a solution comprising lactose in an amount effective to preclude or to reverse cell swelling.

- 65. (Previously presented) The method of claim 64 wherein the lactose comprises alpha lactose.
- 66. (Currently amended) The method of claim 64 wherein the lactose is at a concentration from falls in the range of about 11 mM to about 250 mM.

67-68. (Cancelled)